These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9383842)

  • 1. Acceptability of genital herpes immunization. The role of health beliefs and health behaviors.
    Zimet GD; Fortenberry JD; Fife KH; Tyring SK; Herne K; Douglas JM
    Sex Transm Dis; 1997 Nov; 24(10):555-60. PubMed ID: 9383842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
    Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
    JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of STDs--the role of prophylactic vaccines against herpes simplex virus.
    Stanberry LR
    Sex Transm Infect; 1998 Dec; 74(6):391-4. PubMed ID: 10195045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
    Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
    J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
    Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L
    Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus type 2 in Brazil: seroepidemiologic survey.
    Da Rosa-Santos OL; Gonçalves Da Silva A; Pereira AC
    Int J Dermatol; 1996 Nov; 35(11):794-6. PubMed ID: 8915732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
    Jones CA; Cunningham AL
    Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptance and outcome of herpes simplex virus type 2 antibody testing in patients attending an STD clinic--recognized and unrecognized infections.
    Löwhagen GB; Berntsson M; Bonde E; Tunbäck P; Krantz I
    Acta Derm Venereol; 2005; 85(3):248-52. PubMed ID: 16040412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of prophylactic vaccines for genital and neonatal herpes.
    Jones CA; Cunningham AL
    Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
    Milligan GN; Dudley-McClain KL; Chu CF; Young CG
    Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.
    Wachsman M; Kulka M; Smith CC; Aurelian L
    Vaccine; 2001 Feb; 19(15-16):1879-90. PubMed ID: 11228357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
    Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.
    Bourne N; Milligan GN; Schleiss MR; Bernstein DI; Stanberry LR
    Vaccine; 1996 Sep; 14(13):1230-4. PubMed ID: 8961510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.